The evolution of MRD-guided therapy for leukemia

Richard Dillon, MBBS, from King's College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML). The evolution of MRD-guided therapies is timel... Author: VJHemOnc Added: 07/24/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts